The Asia Pacific Minimal Residual Disease Testing Market would witness market growth of 15.3% CAGR during the forecast period (2022-2028).
Various institutions and organizations are researching the predictive significance of MRD tests in adult patients. Therefore, the outcomes of MRD investigations can be utilized to decide on the type and length of treatment, as well as to calculate the ideal window of time for hematopoietic stem cell transplantation (HSCT).
In addition, the discovery of new leukemia biomarkers and the application of increasingly accurate assays would make routine MRD monitoring even more manageable. This would further raise the significance of MRD tests and will contribute to a better understanding of the cellular and biological characteristics of leukemic cells that withstand chemotherapy in vivo.
The rising incidence of cancer worldwide and the higher acceptance of cancer therapies in developing nations are boosting the demand for MRD tests. The simultaneous shifts in healthcare from diagnosis of disease to early diagnosis or risk assessment and the expanding biomarkers' use in drug development are all contributing factors to the market's expansion.
Cancer is one of the leading causes of death in Asian nations. According to the National Cancer Center, three types of blood cancers, multiple lymphomas, malignant myelomas, and leukemia, also make up a portion of all cancers in Japan. The prevalence of cancer has sharply increased in recent years, and it is predicted that this trend will continue during the forecast period.
The China market dominated the Asia Pacific Minimal Residual Disease Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $211.1 million by 2028.The Japan market is experiencing a CAGR of 14.6% during (2022 - 2028). Additionally, The India market would display a CAGR of 16.1% during (2022 - 2028).
Based on Application, the market is segmented into Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors and Others. Based on End User, the market is segmented into Hospitals & Specialty Clinics, Diagnostic Laboratories, Academic & Research Institutes and Others. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Flow Cytometry and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Minimal Residual Disease Testing Market is Projected to reach USD 2.7 Billion by 2028, at a CAGR of 14.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Rad Laboratories, Inc., Guardant Health, Inc., Invitae Corporation (ArcherDX, Inc.), Bio-Techne Corporation, F. Hoffmann-La Roche Ltd., ICON plc (MolecularMD Corporation), Natera, Inc., Sysmex Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc.
By Application
By End User
By Technology
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
